Enoxaparin Versus Aspirin in Patients With Cancer and Stroke

Any adult patient with active systemic cancer diagnosed with acute ischemic stroke at the main MSKCC campus or at any of MSKCC's New York City outpatient center WCMC, NYPH/CUMC within the prior four weeks would be eligible. Inclusion Criteria: * 18 to 85 years of age. * Active cancer, defined as a pathologic diagnosis of or treatment for any cancer, other than basal-cell or squamous-cell carcinoma of the skin, within the past six months; or patients with known recurrent or metastatic disease within the past six months. * A pathology report issued at the enrolling site confirming the diagnosis of cancer is required for enrollment. * Acute ischemic stroke within the prior four weeks, defined as a new neurologic deficit(s) with MRI evidence of acute ischemia in a referable location, and no clinical or radiologic indication of a non-cerebrovascular mimic, such as a brain metastasis, as the etiology of the deficit(s). Exclusion Criteria: * Inability to get brain MRI * Known malignant primary brain tumor. * Diagnosis of intracranial hemorrhage within the past 3 months, including intratumoral hemorrhage into brain metastases from a systemic cancer. * Active or serious bleeding within two weeks of enrollment. * Patient condition associated with a high risk of bleeding such as recent surgery or peptic ulcer disease. * Clear indication for anticoagulation (e.g., atrial fibrillation) anticipated during the study period. * Clear indication for antiplatelet agents (e.g., cardiac stent…